Award & Investment Overview
McMaster University postdoctoral fellow Manoj Jangra has received the $50,000 top prize in the Heersink ACE50 Pitch Competition for his commercialization plan to advance lariocidins, a promising new class of antibiotics targeting drug-resistant bacterial infections.
Jangra, a researcher in McMaster’s Department of Biochemistry and Biomedical Sciences, led the discovery of lariocidins in the laboratory of Gerry Wright at the Michael G. DeGroote Institute for Infectious Disease Research. The prize will support the planned formation of Hammer Therapeutics, a Hamilton-based university spinout focused on advancing the technology toward therapeutic development.
The award represents an early commercialization milestone, providing non-dilutive capital to support company formation, initial team development, and further research. The technology remains preclinical, and additional validation will be necessary before it can progress toward clinical development or pharmaceutical partnerships.
Approach & Ecosystem Context
The Heersink ACE50 Pitch Competition is part of McMaster University’s entrepreneurship and commercialization support ecosystem. It challenges university innovators to demonstrate the commercial potential of their research and develop credible pathways toward market application.
Jangra prepared for the competition through McMaster’s Masterclass: Foundations of Commercialization, a six-session program covering market sizing, business models, intellectual property, and investor-style pitching. The program helped translate a scientific discovery into a more focused commercial proposition addressing specific unmet needs in antibiotic treatment.
The $50,000 award will help establish Hammer Therapeutics, including company formation, branding, advisory board development, and research personnel support. Jangra will also participate in the six-month Heersink ACE50 Fellowship, which provides coaching and mentorship to refine commercialization plans.
From a Mind the GAP perspective, this award illustrates how modest non-dilutive funding and structured entrepreneurial training can work together to move university research toward venture formation. The prize addresses immediate organizational and development needs, while the fellowship provides continued support as the team prepares for future startup funding and potential pharmaceutical industry partnerships.
McMaster also recognized additional ACE50 recipients across several faculties, including $25,000 awards and a $10,000 audience-selected pitch prize, demonstrating the program’s broader support for university innovation.
Innovation & Technology
Lariocidins: A New Class of Antibiotics
Lead Researchers: Manoj Jangra and Gerry Wright | Planned Spinout: Hammer Therapeutics
Researchers at McMaster University discovered lariocidins, a new class of antibiotics originally identified in soil samples collected in Hamilton, Ontario. Unlike existing antibiotic classes, lariocidins target a previously unexploited site within the bacterial protein-production machinery, offering a potentially differentiated mechanism for treating drug-resistant infections. The discovery was reported in Nature in 2025. Hammer Therapeutics is being planned to advance the compounds through further preclinical research, reduce development risks, and prepare for future therapeutic development and pharmaceutical partnerships.
Potential Market Uses and Applications
Potential Clinical and Therapeutic Applications
- Treatment of bacterial infections resistant to existing antibiotics.
- Development of new therapies for critically ill patients with limited treatment options.
- Hospital-based treatment of difficult-to-treat bacterial infections.
- Development of antibiotics with differentiated mechanisms of action.
Potential Pharmaceutical and Commercialization Applications
- Preclinical antibiotic drug development.
- Licensing and development partnerships with pharmaceutical companies.
- Antimicrobial drug discovery and development.
- University spinout formation and early-stage therapeutic venture financing.
- Further validation of lariocidins as potential clinical candidates.
Related Topics
McMaster University, Heersink ACE50 Pitch Competition, Manoj Jangra, Gerry Wright, Hammer Therapeutics, lariocidins, antibiotic discovery, antimicrobial resistance, antibiotic commercialization, university spinouts, university entrepreneurship, GAP funding, proof-of-concept funding, non-dilutive funding, translational research, pharmaceutical development, technology transfer, Masterclass Foundations of Commercialization, Heersink ACE50 Fellowship, Michael G. DeGroote Institute for Infectious Disease Research, Hamilton biotechnology ecosystem
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
